Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) Equity Income (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Equity Income data on record, last reported at -$323000.0 in Q3 2025.

  • For Q3 2025, Equity Income rose 52.64% year-over-year to -$323000.0; the TTM value through Sep 2025 reached -$1.9 million, up 20.35%, while the annual FY2023 figure was -$5.3 million, 47.19% up from the prior year.
  • Equity Income reached -$323000.0 in Q3 2025 per CRVS's latest filing, up from -$389000.0 in the prior quarter.
  • Across five years, Equity Income topped out at $236000.0 in Q1 2024 and bottomed at -$4.6 million in Q4 2022.
  • Average Equity Income over 4 years is -$1.3 million, with a median of -$953000.0 recorded in 2022.
  • Peak YoY movement for Equity Income: skyrocketed 113.63% in 2024, then plummeted 328.39% in 2025.
  • A 4-year view of Equity Income shows it stood at -$4.6 million in 2022, then surged by 69.73% to -$1.4 million in 2023, then surged by 51.42% to -$682000.0 in 2024, then soared by 52.64% to -$323000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Income were -$323000.0 in Q3 2025, -$389000.0 in Q2 2025, and -$539000.0 in Q1 2025.